Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting1
Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting133%
not_yet_recruiting133%
enrolling_by_invitation133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingnot_applicable

Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)

NCT07006194
enrolling_by_invitationphase_3

Nicotinamide Supplementation in Glaucoma

NCT06731582
recruitingphase_2

The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients

NCT06640309

Clinical Trials (3)

Showing 3 of 3 trials
NCT07006194Not Applicable

Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)

Not Yet Recruiting
NCT06731582Phase 3

Nicotinamide Supplementation in Glaucoma

Enrolling By Invitation
NCT06640309Phase 2

The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
3